14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $14.58 $20.11 Thursday, 2nd May 2024 DNLI stock ended at $16.81. This is 4.02% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 6.41% from a day low at $15.92 to a day high of $16.94.
90 days $14.58 $23.52
52 weeks $14.58 $33.31

Historical Denali Therapeutics Inc. prices

Date Open High Low Close Volume
Jan 29, 2018 $22.32 $24.02 $22.32 $23.95 330 250
Jan 26, 2018 $21.37 $22.31 $20.89 $22.20 133 102
Jan 25, 2018 $21.83 $21.90 $19.09 $21.15 265 288
Jan 24, 2018 $22.31 $22.31 $21.55 $21.80 204 790
Jan 23, 2018 $21.70 $22.25 $21.09 $21.85 392 435
Jan 22, 2018 $19.80 $23.00 $19.80 $21.56 514 991
Jan 19, 2018 $18.41 $20.04 $18.41 $19.76 525 405
Jan 18, 2018 $17.62 $18.45 $17.50 $18.32 279 492
Jan 17, 2018 $17.11 $17.76 $16.65 $17.62 209 043
Jan 16, 2018 $17.16 $17.80 $16.86 $17.10 383 931
Jan 12, 2018 $16.64 $17.25 $16.43 $17.16 314 524
Jan 11, 2018 $15.43 $16.98 $15.17 $16.53 458 969
Jan 10, 2018 $15.50 $15.57 $14.96 $15.36 296 291
Jan 09, 2018 $16.46 $16.54 $15.49 $15.50 273 820
Jan 08, 2018 $16.80 $16.90 $16.40 $16.48 372 574
Jan 05, 2018 $16.88 $17.63 $16.33 $16.80 672 562
Jan 04, 2018 $16.70 $16.76 $16.01 $16.08 279 207
Jan 03, 2018 $16.41 $16.78 $16.25 $16.65 358 120
Jan 02, 2018 $16.00 $16.46 $15.92 $16.13 567 500
Dec 29, 2017 $15.15 $15.80 $14.72 $15.64 264 224
Dec 28, 2017 $15.94 $16.02 $14.83 $15.04 384 998
Dec 27, 2017 $15.48 $16.39 $15.35 $15.85 382 660
Dec 26, 2017 $15.90 $16.50 $15.02 $15.46 299 743
Dec 22, 2017 $16.60 $16.60 $15.75 $15.78 669 121
Dec 21, 2017 $18.01 $18.08 $16.39 $16.45 491 911
Click to get the best stock tips daily for free!

About Denali Therapeutics Inc.

Denali Therapeutics. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for ... DNLI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT